Switch theme
Sign up to access all valuation multiples
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
2000
111
LTM Revenue $21.4M
LTM EBITDA -$18.3M
$177M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
MediWound has a last 12-month revenue of $21.4M and a last 12-month EBITDA of -$18.3M.
In the most recent fiscal year, MediWound achieved revenue of $20.2M and an EBITDA of -$27.9M.
MediWound expects next 12-month revenue of XXX and NTM EBITDA of XXX
See MediWound valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $18.7M | $20.2M | XXX | XXX | XXX |
| Gross Profit | $13.2M | $3.6M | XXX | XXX | XXX |
| Gross Margin | 70% | 18% | XXX | XXX | XXX |
| EBITDA | -$4.8M | -$27.9M | XXX | XXX | XXX |
| EBITDA Margin | -26% | -138% | XXX | XXX | XXX |
| Net Profit | -$19.6M | -$6.7M | XXX | XXX | XXX |
| Net Margin | -105% | -33% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, MediWound's stock price is $17.
MediWound has current market cap of $179M, and EV of $177M.
See MediWound trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $177M | $179M | XXX | XXX | XXX | XXX | $-2.98 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, MediWound has market cap of $179M and EV of $177M.
MediWound's trades at 8.3x LTM EV/Revenue multiple, and -9.6x LTM EBITDA.
Analysts estimate MediWound's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for MediWound and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $177M | XXX | XXX | XXX |
| EV/Revenue | 8.7x | XXX | XXX | XXX |
| EV/EBITDA | -6.3x | XXX | XXX | XXX |
| P/E | -5.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -8.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMediWound's NTM/LTM revenue growth is 22%
MediWound's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, MediWound's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate MediWound's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for MediWound and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -138% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 482% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -116% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 16% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 48% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 44% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 109% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
MediWound acquired XXX companies to date.
Last acquisition by MediWound was XXXXXXXX, XXXXX XXXXX XXXXXX . MediWound acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was MediWound founded? | MediWound was founded in 2000. |
| Where is MediWound headquartered? | MediWound is headquartered in United States of America. |
| How many employees does MediWound have? | As of today, MediWound has 111 employees. |
| Who is the CEO of MediWound? | MediWound's CEO is Mr. Ofer Gonen. |
| Is MediWound publicy listed? | Yes, MediWound is a public company listed on NAS. |
| What is the stock symbol of MediWound? | MediWound trades under MDWD ticker. |
| When did MediWound go public? | MediWound went public in 2014. |
| Who are competitors of MediWound? | Similar companies to MediWound include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of MediWound? | MediWound's current market cap is $179M |
| What is the current revenue of MediWound? | MediWound's last 12-month revenue is $21.4M. |
| What is the current EBITDA of MediWound? | MediWound's last 12-month EBITDA is -$18.3M. |
| What is the current EV/Revenue multiple of MediWound? | Current revenue multiple of MediWound is 8.3x. |
| What is the current EV/EBITDA multiple of MediWound? | Current EBITDA multiple of MediWound is -9.6x. |
| What is the current revenue growth of MediWound? | MediWound revenue growth between 2023 and 2024 was 8%. |
| Is MediWound profitable? | Yes, MediWound is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
